|
Jul 15
|
Bausch + Lomb Maintained at Outperform at RBC Ahead of Q2 Results; Price Target Kept at US$17.00
|
|
Jul 15
|
Bausch Health's Xifaxan Patent Clarity, Policy Commentary in Focus for Q2, RBC Says
|
|
Jul 15
|
Bausch + Lomb Q2 Earnings to Benefit From FX Tailwinds, Eye Drop Sales, RBC Says
|
|
Jul 1
|
Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye
|
|
Jun 30
|
Insider Stock Buying Reaches US$1.54m On Bausch + Lomb
|
|
Jun 30
|
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
|
|
Jun 26
|
Bausch + Lomb Closes Senior Secured Notes Offering, Refinancing And Upsizes US$2.32 Billion Term Loan Facility
|
|
Jun 26
|
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
|
|
Jun 25
|
The Top 5 Analyst Questions From Bausch + Lomb’s Q1 Earnings Call
|
|
Jun 23
|
Barclays Cut Bausch & Lomb Target to $16, Keeping Rating Neutral in Early June
|
|
Jun 18
|
Bausch + Lomb Prices Upsizes and Prices a 675-Million Euro Senior Secured Notes Offering
|
|
Jun 18
|
Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering
|
|
Jun 10
|
Bausch + Lomb Announces Launch of Senior Secured Notes Offering and Refinancing of Credit Agreement
|
|
May 22
|
Bausch + Lomb to Participate in the 2025 Jefferies Global Healthcare Conference
|
|
May 21
|
Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results
|
|
May 21
|
Bausch + Lomb Launches New LUMIFY® Preservative Free Redness Reliever Eye Drops in the United States
|
|
Mar 17
|
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States
|
|
Feb 23
|
How DOGE's 'transparency' could be applied to healthcare
|
|
Feb 20
|
Bausch + Lomb Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 20
|
Q4 2024 Bausch + Lomb Corp Earnings Call
|